Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20558263 | 0.95 | APLNR (0.69) | APLNRHTR2AHTR2CKDM4EPOLB | |
| SCHEMBL2551631 | 0.94 | APLNR (0.67) | APLNRHTR2AHTR2CGRIN1GRIN2A | |
| SCHEMBL14971128 | 0.91 | APLNR (0.75) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL29580030 | 0.91 | APLNR (0.75) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL7768853 | 0.87 | APLNR (0.86) | APLNRHTR2AHTR2CKDM4EMEN1 | |
| SCHEMBL7002432 | 0.86 | APLNR (0.73) | APLNRHTR2AHTR2CGRIN1GRIN2A | |
| SCHEMBL13739103 | 0.85 | APLNR (0.67) | APLNRHTR2AHTR2CGRIN1GRIN2A | |
| SCHEMBL17138360 | 0.85 | APLNR (0.71) | APLNRHTR2AHTR2CGRIN1GRIN2A | |
| SCHEMBL28318209 | 0.84 | APLNR (0.80) | APLNRHTR2AHTR2CPOLBMEN1 | |
| SCHEMBL25386029 | 0.84 | APLNR (0.69) | APLNRHTR2AHTR2CGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737153-B2 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-20060241127-A1 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER HEALTHCARE AG (DE) | 2006-10-26 | — | — | US | disclosed |
| EP-1562935-B1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| EP-1562935-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | Bayer HealthCare AG (DE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004039796-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241127-A1 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | ROCK1, ROCK2, RHOA | APLNR 4225/4885HTR2A 2829/4885HTR2C 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.